Astria Therapeutics (NASDAQ:ATXS) Trading Down 2.4%

Astria Therapeutics, Inc. (NASDAQ:ATXS)’s stock price dropped 2.4% during trading on Wednesday . The stock traded as low as $10.83 and last traded at $10.83. Approximately 12,453 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 972,489 shares. The stock had previously closed at $11.10.

Analyst Upgrades and Downgrades

ATXS has been the subject of a number of research reports. Wedbush reiterated an “outperform” rating and issued a $17.00 price target on shares of Astria Therapeutics in a research note on Tuesday, March 26th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Astria Therapeutics in a research note on Monday, March 25th. Finally, Jefferies Financial Group lifted their target price on Astria Therapeutics from $22.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, March 25th.

Astria Therapeutics Stock Down 0.1 %

The stock has a 50 day simple moving average of $13.61 and a 200 day simple moving average of $9.18. The company has a market capitalization of $578.65 million, a price-to-earnings ratio of -4.50 and a beta of 0.69.

Astria Therapeutics (NASDAQ:ATXS) last issued its earnings results on Monday, March 4th. The biotechnology company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). As a group, analysts forecast that Astria Therapeutics, Inc. will post -1.55 EPS for the current year.

Insider Transactions at Astria Therapeutics

In other Astria Therapeutics news, Director Perceptive Advisors Llc acquired 2,481,350 shares of Astria Therapeutics stock in a transaction dated Thursday, February 1st. The stock was acquired at an average cost of $12.09 per share, for a total transaction of $29,999,521.50. Following the completion of the transaction, the director now owns 4,873,721 shares in the company, valued at approximately $58,923,286.89. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Perceptive Advisors Llc acquired 2,481,350 shares of the stock in a transaction on Thursday, February 1st. The shares were purchased at an average cost of $12.09 per share, for a total transaction of $29,999,521.50. Following the transaction, the director now owns 4,873,721 shares in the company, valued at approximately $58,923,286.89. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Christopher Morabito sold 9,200 shares of Astria Therapeutics stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $11.15, for a total transaction of $102,580.00. The disclosure for this sale can be found here. Insiders own 3.40% of the company’s stock.

Hedge Funds Weigh In On Astria Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of ATXS. Legal & General Group Plc boosted its holdings in Astria Therapeutics by 34.4% in the fourth quarter. Legal & General Group Plc now owns 3,492 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 894 shares in the last quarter. Bank of America Corp DE lifted its position in Astria Therapeutics by 18.4% during the 1st quarter. Bank of America Corp DE now owns 13,162 shares of the biotechnology company’s stock worth $175,000 after acquiring an additional 2,050 shares during the last quarter. Nuveen Asset Management LLC lifted its position in Astria Therapeutics by 2.3% during the 4th quarter. Nuveen Asset Management LLC now owns 102,166 shares of the biotechnology company’s stock worth $785,000 after acquiring an additional 2,290 shares during the last quarter. UBS Group AG lifted its position in Astria Therapeutics by 66,700.0% during the 1st quarter. UBS Group AG now owns 2,672 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 2,668 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in Astria Therapeutics by 416.5% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 2,707 shares during the last quarter. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.